Blood-based biomarkers could revolutionize Alzheimer’s diagnosis and treatment

FHS
June 14, 2024
4:35 am

A recent review outlines the necessary factors for widespread implementation and interpretation of Alzheimer’s disease blood-based biomarkers (BBMs) at the population level, emphasizing the potential for early detection and improved diagnosis.

Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC

A chemotherapy-free regimen combining the investigational therapy eftilagimod alpha with pembrolizumab (Keytruda) showed promising efficacy in a small cohort of patients with recurrent or metastatic

July 13, 2024

DocMorris launches approx. CHF 200 million Convertible Bonds due 2029 – Biotech Investments

DocMorris AG / Key word(s): Bond 17-Apr-2024 / 17:46 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely

April 18, 2024

CDMO: Indena’s Long-Term Vision – Pharmaceutical Technology

Share this article Credit: Kitreel via Shutterstock. Indena CDMO origin: Founded in 1921 by Carlo Boccaccio Inverni and Biagio Alberto Della Beffa and headquartered in

February 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.